The structure-based cancer-related single amino acid variation prediction.

Single amino acid variation (SAV) is an amino acid substitution of the protein sequence that can potentially influence the entire protein structure or function, as well as its binding affinity. Protein destabilization is related to diseases, including several cancers, although using traditional experiments to clarify the relationship between SAVs and cancer uses much time and resources. Some SAV prediction methods use computational approaches, with most predicting SAV-induced changes in protein stability.

Comprehensive breast cancer adjuvant digital summary.

Background: Patients with breast cancer often fail to recall the details of their original diagnosis and adjuvant therapy with the passage of time. Subsequent follow-up and treatment at a later time and a different institution wastes valuable time and effort to retrieve the original data.

Patients And Methods: Twenty-five consecutive patients with breast cancer of all stages admitted for adjuvant/neoadjuvant treatment and surgical excision were entered on study.

Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.

We conducted a phase II study of docetaxel and gemcitabine chemotherapy in patients with non-small-cell lung cancer (NSCLC) who had not responded to previous chemotherapy, to assess the response to and toxicity of this combination chemotherapy. Thirty-six patients were enrolled from June 1999 to December 1999. Treatment consisted of docetaxel 30 mg/m(2) and gemcitabine 800 mg/m(2) intravenous infusion on days 1 and 8 every 3 weeks.

Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients.

Purpose: A phase II and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism.

Material And Methods: GL331 was given at 200 mg/m(2) as a daily 3-h infusion for 5 days every 4 weeks.

Results: Enrolled in the study were 15 patients.